AR062731A1 - Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion. - Google Patents
Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion.Info
- Publication number
- AR062731A1 AR062731A1 ARP070103999A ARP070103999A AR062731A1 AR 062731 A1 AR062731 A1 AR 062731A1 AR P070103999 A ARP070103999 A AR P070103999A AR P070103999 A ARP070103999 A AR P070103999A AR 062731 A1 AR062731 A1 AR 062731A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- heterocyclic ring
- cycloalkyl
- halogen
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 15
- 150000002367 halogens Chemical class 0.000 abstract 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 125000001424 substituent group Chemical group 0.000 abstract 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 7
- 125000004043 oxo group Chemical group O=* 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 2
- 101150020251 NR13 gene Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- -1 cyanoC1-3alkyl Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a un derivado de quinazolinona o isoquinolinona de formula (1) donde R1 es alquilo C1-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-3, alquenilo C2-6, alquinilo C2-6, estando dichos alquilo C1-6, cicloalquilo C3-6 y cicloalquil C3-6-alquilo C1-3 opcionalmente sustituidos con hidroxi, alquiloxi C1-6, ciano o uno o más halogenos; R2 es arilo C1-6 opcionalmente sustituido con uno a tres sustituyentes seleccionados entre halogeno, hidroxi, ciano, alquilo C1-6, cicloalquilo C3-6, alquiloxi C1-6, cicloalquiloxi C3-6, estando dichos alquilo C1-6, cicloalquilo C3-6, alquiloxi C1-6 y cicloalquiloxi C3-6, opcionalmente sustituidos con uno o más halogenos; o R2 es un sistema de anillo heteroarilo de 5-10 miembros que comprende un heteroátomo seleccionado entre N, O y S, y está opcionalmente sustituido con un sustituyente seleccionado entre metilo, alquiloxi C1-6 y halogeno; o R2 es cicloalquilo C4-7; R3 es un sustituyente opcional seleccionado entre. alquilo C1-6, alquiloxi C1-6 y halogeno, estando dicho alquilo C1-6 y alquiloxi C1-6 opcionalmente sustituidos con uno o más halogenos; R4 es un grupo ubicado en la posicion 6 o 7 del anillo quinazolinona o isoquinolinona y tiene la formula 2, donde R5 junto con uno de R6 forman un anillo heterocíclico saturado o no saturado de 4-8 miembros que opcionalmente comprende una especie heteroatomica adicional seleccionada entre O, S y NR9, estando dicho anillo heterocíclico opcionalmente sustituido con uno o dos sustituyentes seleccionados entre metilo, halogeno, hidroxi y oxo, o R5 junto con uno de R7 y R8 forman un anillo heterocíclico de 6-8 miembro opcionalmente sustituido con uno o dos sustituyentes seleccionados entre metilo, halogeno, hidroxi y oxo; cada R6 es independientemente H, halogeno o alquilo C1-4 opcionalmente sustituido con halogeno o SO2CH3, o uno de R6 junto con R5 forman un anillo heterocíclico saturado o no saturado de 4-8 miembros que opcionalmente comprende una especie heteroatomica adicional seleccionada entre O, S y NR9, estando dicho anillo heterocíclico opcionalmente sustituido con tino o dos sustituyentes seleccionados entre metilo, halogeno, hidroxi y oxo; R7 y R8 son independientemente H, alquilo C1-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-3, cianoC1-3alquilo, arilo C6-10, aril C6-10-alquilo C1-3, alquiloxi C1-3-alquilo C1-3 o acilo C1-6, estando dichos alquilo C1-6, cicloalquilo C3-6 y cicloalquil C3-6-alquilo C1-3 opcionalmente sustituidos con hidroxi, uno o más halogenos o dialquilamino C1-2; o R7 y R8, junto con el nitrogeno al cual están unidos, forman un anillo heterocíclico saturado o no saturado de 4-8 miembros que opcionalmente comprende una especie heteroatomica adicional seleccionada entre O, S y NR10, estando dicho anillo heterocíclico opcionalmente sustituido con uno o dos sustituyentes seleccionados entre alquilo C1-6, halogeno, hidroxi, alquiloxi C1-6, ciano y COOR11; o uno de R7 y R8 es Y, CH2Y o CH2CH2Y, donde Y es un anillo heterocíclico saturado de 4-6 miembros que comprende una especie heterocíclica seleccionada entre O, SO2 y NR10, estando dicho anillo opcionalmente sustituido con 1-2 sustituyentes seleccionados entre metilo o halogeno; o uno de R7 o R8 junto con R5 forman un anillo heterocíclico de 6-8 miembros que está opcionalmente sustituido con uno o dos sustituyentes seleccionados entre metilo, halogeno, hidroxi y oxo; o uno de R7 y R8 junto con R12 forman un anillo heterocíclico saturado o no saturado de 4-8 miembros que opcionalmente comprende una especie heteroatomica adicional seleccionada entre O, S y NR13, estando dicho anillo heterocíclico opcionalmente sustituido con uno o dos sustituyentes seleccionados entre metilo, hidroxi y oxo; R9 y R10 son independientemente H, alquilo C1-6 o acilo C1-6; R11 es H o alquilo C1-6; cada R12 es independientemente H o alquilo C1-4, o uno de R12 junto con uno de R7 o R8 forman un anillo heterocíclico saturado o no saturado de 4-8 miembros que opcionalmente comprende una especie heteroatomica adicional seleccionada entre O, S y NR13, estando dicho anillo heterocíclico opcionalmente sustituido con uno o dos sustituyentes seleccionados entre metilo, hidroxi y oxo; R13 es H, alquilo C1-6 o acilo C1-6; m es 2-3; y X es N o CH; o una sal o solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84371806P | 2006-09-11 | 2006-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062731A1 true AR062731A1 (es) | 2008-11-26 |
Family
ID=39184483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103999A AR062731A1 (es) | 2006-09-11 | 2007-09-11 | Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7820649B2 (es) |
| EP (1) | EP2069315B1 (es) |
| JP (1) | JP5256202B2 (es) |
| KR (1) | KR20090107994A (es) |
| CN (1) | CN101600698B (es) |
| AR (1) | AR062731A1 (es) |
| AT (1) | ATE523500T1 (es) |
| AU (1) | AU2007296634B2 (es) |
| CA (1) | CA2663161C (es) |
| CL (1) | CL2007002635A1 (es) |
| CO (1) | CO6160322A2 (es) |
| EC (1) | ECSP099177A (es) |
| IL (1) | IL197530A0 (es) |
| MX (1) | MX2009002686A (es) |
| NO (1) | NO20091012L (es) |
| NZ (1) | NZ575426A (es) |
| PE (1) | PE20080841A1 (es) |
| RU (1) | RU2009113612A (es) |
| TW (1) | TW200827352A (es) |
| WO (1) | WO2008033764A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010229035A (ja) * | 2007-08-01 | 2010-10-14 | Taisho Pharmaceutical Co Ltd | ピリドピリミジン−４−オン誘導体 |
| WO2009130231A1 (en) * | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists |
| JP5369721B2 (ja) * | 2009-01-30 | 2013-12-18 | 大正製薬株式会社 | ピリドピリミジン−４−オン誘導体 |
| EP2488520B1 (en) | 2009-10-13 | 2015-09-02 | Merck Sharp & Dohme B.V. | Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor |
| MX2013003633A (es) | 2010-10-01 | 2013-04-24 | Taisho Pharmaceutical Co Ltd | Derivado de 1, 2, 4-triazolona. |
| KR101998442B1 (ko) | 2011-10-27 | 2019-07-09 | 다이쇼 세이야꾸 가부시끼가이샤 | 아졸 유도체 |
| AU2013241076A1 (en) * | 2012-03-30 | 2014-10-09 | Taisho Pharmaceutical Co., Ltd. | Fused azole derivative |
| MA37756B1 (fr) | 2012-06-13 | 2018-09-28 | Hoffmann La Roche | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane |
| SI2900669T1 (sl) | 2012-09-25 | 2019-12-31 | F. Hoffmann-La Roche Ag | Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| UA118201C2 (uk) | 2013-11-26 | 2018-12-10 | Ф. Хоффманн-Ля Рош Аг | НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| US10030010B2 (en) | 2014-08-04 | 2018-07-24 | Sandoz Ag | Route of synthesis for the preparation of suvorexant |
| US9617226B2 (en) | 2014-09-05 | 2017-04-11 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
| MA41898A (fr) * | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| PE20180479A1 (es) | 2015-09-04 | 2018-03-07 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| EP3353176B1 (en) | 2015-09-24 | 2022-01-19 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
| JP6845230B2 (ja) | 2015-09-24 | 2021-03-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| EP3353178B1 (en) | 2015-09-24 | 2021-07-14 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| LT3386591T (lt) | 2015-12-09 | 2020-10-12 | Cadent Therapeutics, Inc. | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas |
| ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
| US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
| CN110392679B (zh) | 2017-03-16 | 2023-04-07 | 豪夫迈·罗氏有限公司 | 可用作双重atx/ca抑制剂的杂环化合物 |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| JP7319369B2 (ja) | 2018-08-03 | 2023-08-01 | ノバルティス アーゲー | ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用 |
| CN111100063B (zh) * | 2018-10-25 | 2022-05-17 | 南京药石科技股份有限公司 | 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法 |
| CN116751169B (zh) * | 2023-06-05 | 2025-08-29 | 重庆市畜牧科学院 | 一种n-(2-氧代丙基)乙酰胺衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2506767A1 (fr) * | 1981-05-26 | 1982-12-03 | Synthelabo | Derives heterocycliques d'amidoximes, leur preparation et leur application en therapeutique |
| ATE366250T1 (de) | 1997-04-25 | 2007-07-15 | Janssen Pharmaceutica Nv | Chinazolinone die farnesyltransferase hemmen |
| IL139199A (en) | 1999-11-02 | 2006-10-31 | Nihon Nohyaku Co Ltd | Derivatives of aminoquinazolinone (thion) or their salts, their intermediates, pesticides and method of use |
| FR2804114B1 (fr) * | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| FR2842527B1 (fr) | 2002-07-19 | 2005-01-28 | Sanofi Synthelabo | Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique |
| ES2302174T3 (es) * | 2004-01-16 | 2008-07-01 | F. Hoffmann-La Roche Ag | Derivados 1-bencil-5-piperacin-1-il-3,4-dihidro-1h-quinazolin-2-ona y derivados respectivos de 1h-benzo(1,2,6)tiadiacin-2,2-dioxido y 1,4-dihidro-benzo(d)(1,3)oxacin-2-ona como moduladores del receptor 5-hidroxitriptamina(5-ht) para tratamiento enfermed. sistema nervioso central. |
| CN1960977B (zh) * | 2004-05-31 | 2010-07-21 | 万有制药株式会社 | 喹唑啉衍生物 |
| WO2006012577A2 (en) * | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
| TW200643015A (en) * | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| MX2009002685A (es) * | 2006-09-11 | 2009-10-13 | Organon Nv | Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il). |
-
2007
- 2007-09-10 EP EP07842157A patent/EP2069315B1/en active Active
- 2007-09-10 WO PCT/US2007/078022 patent/WO2008033764A2/en not_active Ceased
- 2007-09-10 MX MX2009002686A patent/MX2009002686A/es not_active Application Discontinuation
- 2007-09-10 AU AU2007296634A patent/AU2007296634B2/en active Active
- 2007-09-10 JP JP2009527608A patent/JP5256202B2/ja not_active Expired - Fee Related
- 2007-09-10 KR KR1020097007035A patent/KR20090107994A/ko not_active Withdrawn
- 2007-09-10 NZ NZ575426A patent/NZ575426A/en not_active IP Right Cessation
- 2007-09-10 AT AT07842157T patent/ATE523500T1/de not_active IP Right Cessation
- 2007-09-10 RU RU2009113612/04A patent/RU2009113612A/ru unknown
- 2007-09-10 CA CA2663161A patent/CA2663161C/en active Active
- 2007-09-10 US US11/852,762 patent/US7820649B2/en active Active
- 2007-09-10 CN CN2007800416250A patent/CN101600698B/zh active Active
- 2007-09-11 TW TW096133906A patent/TW200827352A/zh unknown
- 2007-09-11 PE PE2007001221A patent/PE20080841A1/es not_active Application Discontinuation
- 2007-09-11 CL CL2007002635A patent/CL2007002635A1/es unknown
- 2007-09-11 AR ARP070103999A patent/AR062731A1/es not_active Application Discontinuation
-
2009
- 2009-03-06 NO NO20091012A patent/NO20091012L/no not_active Application Discontinuation
- 2009-03-11 IL IL197530A patent/IL197530A0/en unknown
- 2009-03-11 EC EC2009009177A patent/ECSP099177A/es unknown
- 2009-04-08 CO CO09036257A patent/CO6160322A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2069315B1 (en) | 2011-09-07 |
| NO20091012L (no) | 2009-03-26 |
| MX2009002686A (es) | 2009-10-13 |
| PE20080841A1 (es) | 2008-06-14 |
| RU2009113612A (ru) | 2010-10-20 |
| CO6160322A2 (es) | 2010-05-20 |
| JP2010502746A (ja) | 2010-01-28 |
| KR20090107994A (ko) | 2009-10-14 |
| EP2069315A4 (en) | 2010-11-03 |
| CN101600698A (zh) | 2009-12-09 |
| CA2663161C (en) | 2014-10-28 |
| TW200827352A (en) | 2008-07-01 |
| CN101600698B (zh) | 2012-01-11 |
| EP2069315A2 (en) | 2009-06-17 |
| CL2007002635A1 (es) | 2009-10-23 |
| WO2008033764A2 (en) | 2008-03-20 |
| CA2663161A1 (en) | 2008-03-20 |
| ATE523500T1 (de) | 2011-09-15 |
| WO2008033764A3 (en) | 2008-12-18 |
| AU2007296634B2 (en) | 2012-09-20 |
| US7820649B2 (en) | 2010-10-26 |
| US20080090802A1 (en) | 2008-04-17 |
| NZ575426A (en) | 2010-09-30 |
| IL197530A0 (en) | 2009-12-24 |
| AU2007296634A1 (en) | 2008-03-20 |
| JP5256202B2 (ja) | 2013-08-07 |
| ECSP099177A (es) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062731A1 (es) | Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion. | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR057209A1 (es) | Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas | |
| AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
| AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
| AR074790A1 (es) | Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente. | |
| CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR103969A1 (es) | Inmunomoduladores | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
| AR059513A1 (es) | Derivados benzoil - piperidina como moduladores de 5ht/ d3 | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR062734A1 (es) | Derivados de 2-(1-oxo-1h-isoquinolin-2-il)acetamida | |
| AR104528A1 (es) | Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| AR046170A1 (es) | Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |